Histone modifications represent a critical epigenetic mechanism regulating gene expression in neurodegenerative diseases. Post-translational modifications of histone proteins—including acetylation, methylation, phosphorylation, ubiquitination, and sumoylation—directly influence chromatin structure and transcriptional programs important for neuronal survival, synaptic plasticity, and protein homeostasis. Dysregulation of these modifications has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) [1][1].
This pathway page documents the major histone modification enzymes, their alterations in neurodegenerative diseases, and therapeutic targeting strategies.
Histone acetyltransferases catalyze the addition of acetyl groups to lysine residues on histone tails, generally promoting gene transcription by neutralizing positive charge and relaxing chromatin structure.
| HAT | Function | Disease Association | Therapeutic Target |
|---|---|---|---|
| p300/CBP | Master transcriptional coactivator | Reduced in AD brains | HDAC inhibitors indirect activation |
| PCAF | Learning and memory | Impaired in AD | - |
| GCN5 | Embryonic development | Altered in PD | - |
| TIP60 | Neuronal viability | Decreased in AD | - |
Key Findings:
Histone deacetylases remove acetyl groups, generally repressing transcription. Six classes exist: Class I (HDACs 1,2,3,8), Class IIa (HDACs 4,5,7,9), Class IIb (HDACs 6,10), Class III (sirtuins SIRT1-7), Class IV (HDAC11).
| HDAC | Class | Expression in Disease | Therapeutic Status |
|---|---|---|---|
| HDAC1 | I | Elevated in AD | - |
| HDAC2 | I | Increased in AD, suppresses memory genes | Target for inhibitors |
| HDAC3 | I | Elevated in PD models | - |
| HDAC4 | IIa | Nuclear localization in AD | - |
| HDAC5 | IIa | Mislocalized in HD | - |
| HDAC6 | IIb | Increases in AD, targets tau | HDAC6 inhibitors in trials |
| SIRT1 | III | Decreased in AD | SIRT1 activators (resveratrol) |
| SIRT2 | III | Elevated in PD | SIRT2 inhibitors |
Therapeutic Implications:
Histone methyltransferases add methyl groups to lysine or arginine residues. Unlike acetylation, methylation can be depending on the residue modified.
| Enzyme | Modification | Function | Disease Link |
|---|---|---|---|
| SUV39H1 | H3K9me3 | Heterochromatin formation | Reduced in AD |
| SUV39H2 | H3K9me3 | Pericentric heterochromatin | - |
| EZH2 | H3K27me3 | Polycomb repression | Increased in ALS |
| MLL1/2 | H3K4me3 | Active transcription | Altered in PD |
| PRDM2 | H3K9me2 | Repression | Reduced in AD |
| Enzyme | Target | Function | Disease Link |
|---|---|---|---|
| LSD1/KDM1A | H3K4me2, H3K9me2 | Demethylation | Elevated in AD |
| JMJD2/KDM4 | H3K9me3, H3K36me3 | Chromatin regulation | Increased in PD |
| UTX/KDM6A | H3K27me3 | Activates transcription | Mutated in some FTD |
| JARID1/KDM5 | H3K4me3 | Repression | Elevated in ALS |
Key Findings:
Histone phosphorylation, particularly of H2AX (γH2AX), is a hallmark of DNA damage response.
| Modification | Enzyme | Function | Disease Relevance |
|---|---|---|---|
| H2AX S139 | ATM/ATR | DNA damage marker | Increased in PD, AD |
| H3 S10 | Aurora kinases | Chromosome condensation | Mitotic defects in AD |
| H3 T3 | Haspin | Mitotic regulation | - |
| H3 S28 | MSK1/2 | Stress response | Altered in AD |
γH2AX as Biomarker:
| Enzyme | Modification | Function | Disease Link |
|---|---|---|---|
| RNF20 | H2Bub1 | Transcription activation | Reduced in AD |
| RNF40 | H2Bub1 | Co-transcriptional | Decreased in PD |
| BMI1/Ring1A | H2AK119ub | Polycomb repression | Reduced in AD |
| Enzyme | Target | Function | Disease Link |
|---|---|---|---|
| UBC9 | SUMO conjugation | Protein modification | Altered in PD |
| SENP1 | SUMO removal | Desumoylation | Increased in AD |
| SENP2 | SUMO removal | Desumoylation | - |
Key Findings:
Histone modifications do not act in isolation—they form a complex network of cross-talk:
| Drug | Target | Disease | Status |
|---|---|---|---|
| Valproic acid | Class I HDACs | AD | Phase 2/3 |
| Vorinostat | Class I/II HDACs | HD | Phase 2 |
| Sodium phenylbutyrate | Pan-HDAC | ALS | Phase 2 |
| RGFP109 | HDAC1/3 | AD | Preclinical |
| ACY-1215 | HDAC6 | AD | Preclinical |
| Compound | Target | Disease | Status |
|---|---|---|---|
| Resveratrol | SIRT1 | AD | Phase 2 |
| SRT2104 | SIRT1 | AD | Phase 1 |
| EX-527 | SIRT6 | PD | Preclinical |
Overall Confidence: 6.7/10 (Moderate)
| Dimension | Score |
|---|---|
| Supporting Studies | 10.0/10 |
| Replication Across Labs | 3.0/10 |
| Effect Sizes | 0.0/10 |
| Evidence Confidence | 8.0/10 |
| Mechanistic Completeness | 10.0/10 |
Confidence assessment based on literature evidence quality and mechanistic depth.
(Add references here)